... eukaryotic plasmids containing either one type of HBV YMDD mutant or wild-type strains ... experimental basis for further in vitro studies on HBV lamivudine-resistant mutants.
The successful construction ...
... eukaryotic plasmids containing either one type of HBV YMDD mutant or wild-type strains, ... allow systematic studies on the combined effects of HBV genotype together with lamivudine-resistant mutations, ...
HBV infection remains a major health problem in the world. Several data have revealed that lamivudine can efficiently promote the treatment of hepatitis B...
... of checkpoint proteins on different levels. The implication of this is that with time, persistent HBV infection may lead to the accumulation of a variety of mutations which would ultimately give rise ...
... with the clinical outcome of liver disease, however, this is still controversial. It is likely that this depends on the HBV genotype distribution in certain region. So far, there is no such data from ...
... B-infected mothers, according to the study.
"These data suggest that the effectiveness of the universal HBV immunization program to prevent hepatocellular carcinoma has extended beyond childhood and ...
... 14, 2008, in the World Journal of Gastroenterology.
The heterogeneity in the global distribution of HBV genotypes may account for differences in the clinical outcomes of HBV infections and in the ...
... HBV, however the virus commonly becomes resistant to it and leads to disease progression. Adefovir dipivoxil ... year of treatment increased the proportion of patients with HBV DNA <300 copies/mL from 21 ...
Infection with hepatitis B virus (HBV) causes liver cancer in some individuals, but not all strains of the virus are associated with the same degree of risk. If confirmed, the newly reported data ...
... is to determine whether secondary prevention can be accomplished with new antiviral therapies for HBV infection," the editorialists write. When secondary prevention strategies are tested in large ...
... assume that early intervention of DNA damage pathway will function more efficiently, thus can be used clinically as HBV infection therapy during its early infectious stage or fulminant HBV infection.
... would be recommended the lamivudine use before immunological suppression.
After this study, it was recommended HBV vaccination for IBD patients that have never been infected by BV and also recommend ...
... . In these cases, the M. D. Anderson researchers say, there is a potential for reactivation of HBV during chemotherapy, the most common treatment for pancreatic cancer. Chemotherapy may suppress the ...
... only evaluated in restricted and small groups of patients between those with established chronicity and subjects with acute HBV infection. Besides, whether levels of PD-1 expression on T cells differ ...
Lamivudine has a high rate of antiviral resistance. Sequential anti-HBV treatment is commonly used for lamivudine resistance. An article was published on 21 July 2008 of the World Journal of ...
